Melissa Martin1, Biyao Zou2, Joseph Hoang2, Donghak Jeong2, Rachel Bensen1, Mindie H Nguyen3. 1. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Stanford University School of Medicine, 780 Welch Road, RM CJ250K, Palo Alto, CA, 94304, USA. 2. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 780 Welch Road, RM CJ250K, Palo Alto, CA, 94304, USA. 3. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 780 Welch Road, RM CJ250K, Palo Alto, CA, 94304, USA. mindiehn@stanford.edu.
Abstract
BACKGROUND: Adult liver-related hospitalizations have recently increased in the USA, but data are limited for the pediatric population. AIMS: Utilizing the Office of Statewide Health Planning and Development hospital claims database (covering > 98% of all California hospitalizations), we aimed to characterize the demographic, clinical, and socioeconomic factors of liver disease-associated admissions among children between 2005 and 2015. METHODS: We used ICD-9 codes to identify admissions associated with liver disease in patients up to 21 years of age. Patient characteristics were described as percentages and evaluated using the χ2 test. We used linear regression to examine changes over time. RESULTS: We analyzed 37,372 eligible admissions. Overall, close to one-third (28%) and one-half (48.0%) of admissions occurred in the age group 0-5 years and 16-21 years, respectively, with the remaining 23.1% occurring in the age group between 5 and 15 years. Over half (54.9%) were in males. By race, blacks made up half of the admission (49.7%), while by ethnicity, Hispanic also accounted for half of the admission (49.7%). Medicaid and Medicare payors were also disproportionately represented (54.6%). The most common liver disease was Alagille syndrome (29.2%) in 2005. Between 2005 and 2015, both the number of pediatric liver-associated admissions and the proportion of pediatric liver admissions over total admissions increased from 3130 to 3429 and 1.2% to 1.6%, respectively (both p = 0.001). By 2015, while Alagille syndrome admissions decreased to 26.4% (p = 0.004), NAFLD admission increased to 19.7% (p < 0.001). CONCLUSION: Major disparities exist in inpatient liver disease burden for blacks and Hispanics with liver disease, while NAFLD emerged as a rapidly rising liver disease in pediatrics.
BACKGROUND: Adult liver-related hospitalizations have recently increased in the USA, but data are limited for the pediatric population. AIMS: Utilizing the Office of Statewide Health Planning and Development hospital claims database (covering > 98% of all California hospitalizations), we aimed to characterize the demographic, clinical, and socioeconomic factors of liver disease-associated admissions among children between 2005 and 2015. METHODS: We used ICD-9 codes to identify admissions associated with liver disease in patients up to 21 years of age. Patient characteristics were described as percentages and evaluated using the χ2 test. We used linear regression to examine changes over time. RESULTS: We analyzed 37,372 eligible admissions. Overall, close to one-third (28%) and one-half (48.0%) of admissions occurred in the age group 0-5 years and 16-21 years, respectively, with the remaining 23.1% occurring in the age group between 5 and 15 years. Over half (54.9%) were in males. By race, blacks made up half of the admission (49.7%), while by ethnicity, Hispanic also accounted for half of the admission (49.7%). Medicaid and Medicare payors were also disproportionately represented (54.6%). The most common liver disease was Alagille syndrome (29.2%) in 2005. Between 2005 and 2015, both the number of pediatric liver-associated admissions and the proportion of pediatric liver admissions over total admissions increased from 3130 to 3429 and 1.2% to 1.6%, respectively (both p = 0.001). By 2015, while Alagille syndrome admissions decreased to 26.4% (p = 0.004), NAFLD admission increased to 19.7% (p < 0.001). CONCLUSION: Major disparities exist in inpatient liver disease burden for blacks and Hispanics with liver disease, while NAFLD emerged as a rapidly rising liver disease in pediatrics.
Authors: Tamara D Simon; Jay Berry; Chris Feudtner; Bryan L Stone; Xiaoming Sheng; Susan L Bratton; J Michael Dean; Rajendu Srivastava Journal: Pediatrics Date: 2010-09-20 Impact factor: 7.124
Authors: Katherine H Burns; Patrick H Casey; Robert E Lyle; T Mac Bird; Jill J Fussell; James M Robbins Journal: Pediatrics Date: 2010-09-20 Impact factor: 7.124
Authors: Pamela C Heaton; Namita L Tundia; Nicole Schmidt; Patricia R Wigle; Christina M L Kelton Journal: J Pediatr Gastroenterol Nutr Date: 2012-04 Impact factor: 2.839
Authors: Yen H Pham; Brigid A Bingham; Cynthia S Bell; Susan A Greenfield; Susan D John; Lawrence H Robinson; Mona A Eissa Journal: South Med J Date: 2016-03 Impact factor: 0.954
Authors: A E Feldstein; P Charatcharoenwitthaya; S Treeprasertsuk; J T Benson; F B Enders; P Angulo Journal: Gut Date: 2009-07-21 Impact factor: 23.059
Authors: JoAnna K Leyenaar; Shawn L Ralston; Meng-Shiou Shieh; Penelope S Pekow; Rita Mangione-Smith; Peter K Lindenauer Journal: J Hosp Med Date: 2016-07-04 Impact factor: 2.960